Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Semaglutide Formulations and Devices
NCT03598621Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Jul 2018
- Primary completion
- Jan 2019
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of semaglutide in type 2 diabetes mellitus (T2DM) (3 cohorts), sponsored by Novo Nordisk. Primary endpoints: Area under the plasma semaglutide concentration curve from time 0 until last quantifiable measurement and Maximum plasma semaglutide concentration. Started Jul 2018; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03598621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03598621.